<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02846012</url>
  </required_header>
  <id_info>
    <org_study_id>2016-NxGeM-01</org_study_id>
    <nct_id>NCT02846012</nct_id>
  </id_info>
  <brief_title>Comparison of Culture Media for in Vitro Embryo Development</brief_title>
  <acronym>NXGeM</acronym>
  <official_title>Prospective Observational Study Utilizing Next Generation Continuous Single Culture Media (CSCM2) for Comparative in Vitro Embryo Development and Outcome Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ovation Fertility</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ovation Fertility</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect development and outcome data on human embryos which&#xD;
      are cultured in a 2nd generation continuous single culture medium (CSCM2) with the objective&#xD;
      to demonstrate its performance efficacy in comparison to existing commercially available&#xD;
      single culture or continuous embryo culture media.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A multi-center (3 sites and 2 investigators), prospective trial with up to 300 patients.&#xD;
      Patients will be enrolled from participating sites from the United States. Study sites will&#xD;
      conduct this study under the oversight of Sterling IRB. Each study site should enroll enough&#xD;
      patients to achieve at least 50 evaluable patients that have undergone a treatment cycle&#xD;
      using split case sibling embryos in which half of the embryos are cultured in CSCM2 and the&#xD;
      other half in current CSCM (as control).&#xD;
&#xD;
      The methods will consist of standard ovarian stimulation protocols at each facility to obtain&#xD;
      a sufficient number of mature (MII) oocytes for fertilization by ICSI. Following&#xD;
      fertilization, identified diploid (2PN) zygotes will be evenly divided and randomly allocated&#xD;
      to the embryo culture treatment conditions of CSCM2 or CSCM and cultured according to&#xD;
      standard laboratory procedure (incubated in 5-6% CO2 in air or low O2 concentrations of 5-6%)&#xD;
      to the blastocyst stage (Day 5/6 or 7). Top quality blastocyst(s) will be transferred and&#xD;
      monitored for implantation, pregnancy and ongoing birth. Embryo transfers will either occur&#xD;
      in a fresh or frozen cycle.&#xD;
&#xD;
      The procedures in this study are designed to follow the standard medical care at each study&#xD;
      site for women having IVF treatment (the participant will sign a separate consent at your&#xD;
      clinic for your IVF procedures). The participants study doctor will explain in detail the&#xD;
      procedures participants will undergo at the clinic; this form is only meant to explain the&#xD;
      details of the research study. This study does not involve randomization of patient&#xD;
      participation or any sham procedures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Success</measure>
    <time_frame>2 years</time_frame>
    <description>Live Birth</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation</measure>
    <time_frame>2 years</time_frame>
    <description>Presence of Gestational Sac</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Development</measure>
    <time_frame>2 years</time_frame>
    <description>Blastocyst Utilisation Rate (number of fertilised embryos which develop to usable blastocysts)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>CSCM Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSCM2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New Formulation medium</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CSCM2</intervention_name>
    <arm_group_label>CSCM2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age in good general physical and mental health.&#xD;
&#xD;
          -  Women undergoing fresh in vitro fertilization treatment using their own eggs which&#xD;
             will be fertilized by ICSI only&#xD;
&#xD;
          -  Normal uterine cavity, as defined by the program.&#xD;
&#xD;
          -  Normal BMI (&lt; 35).&#xD;
&#xD;
          -  Normal endocrine workup (including PCOS patients).&#xD;
&#xD;
          -  Fresh or Frozen Blastocyst transfer&#xD;
&#xD;
          -  At least 4 diploid zygotes showing signs of normal (2PN) fertilisation&#xD;
&#xD;
          -  Willing to have half of their 2PN embryos cultured in CSCM and the other half of their&#xD;
             2PN embryos cultured in CSCM 2nd generation&#xD;
&#xD;
          -  Willing to comply with study protocol and procedures&#xD;
&#xD;
          -  Willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of donor egg / gestational carrier&#xD;
&#xD;
          -  Couples for whom the male partner requires surgically extracted sperm (testicular or&#xD;
             epididymal retrieval)&#xD;
&#xD;
          -  History of complications related to tolerance to OCP's, Gonadotropins, Progesterone or&#xD;
             estrogen.&#xD;
&#xD;
          -  A medical condition that is contraindicated to pregnancy or gonadotropin therapy (eg.&#xD;
             allergies, immune deficiency, etc.)&#xD;
&#xD;
          -  History of cancer&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>51 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew VerMilyea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ovation Fertility</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ovation Fertility - Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ovation Fertility</investigator_affiliation>
    <investigator_full_name>Matthew VerMilyea</investigator_full_name>
    <investigator_title>Laboratory Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared, however, collated data may be used for publication without patient identification.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

